Generics Industry Braces For New Wave Of Price Pressure

US Price Erosion Set For Double-Digits; Pricing And Costs Bite In Europe

With pricing pressures already creeping up in recent years, 2022 is set to see the generics industry caught in the middle as prices are further squeezed while costs continue to rise. As major players prepare to announce their first-quarter financial results, Generics Bulletin looks at views from industry leaders on how these pressures are affecting their businesses, and how they can be expected to play out.

Dollar Sign in Vise Vice Price Squeeze
Industry faces pressure as prices are squeezed and costs rise • Source: Design Pics / Alamy Stock Photo

Low pricing has always been something of a double-edged sword for the generics industry. While offering cheaper alternatives to branded products and allowing expanded access to medicines are fundamental components of the off-patent sector’s value proposition, heavy price pressures can create an environment in which generics businesses operating on already thin margins are simply no longer sustainable. This can threaten to force certain products or suppliers out of the market entirely, reducing competition rather than enhancing it.

The generics industry – especially in the US where a limited number of buyers control much of the market –...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Drug Pricing

GB-Policy&Regulation (Premium-1): Lead Exposure Is Still a Problem for Kids, and the Pandemic Has Made It Worse

 
• By 

Video provides a powerful way to help you prove your point. When you click Online Video, you can paste in the embed code for the video you want to add. You can also type a keyword to search online for the video that best fits your document.

Polpharma And MSN Labs Team Up On Distribution

 
• By 

Polpharma has struck a deal with MSN Laboratories that will see the Polish generics player distribute the Indian firm’s hospital portfolio in Poland.

FDA Approves Accord’s Higher Strength Herceptin Biosimilar

 
• By 

Following the FDA’s approval of A 150mg version of Accord’ Herceptin biosimilar, the US agency has now greenlit a higher 400mg strength version of the rival.

‘It’s Not Going To Be An Easy Market’ – Hikma Talks Strategy For US Biosimilars

 
• By 

During Hikma’s first-half results call, the company delved into details of its strategic goals for biosimilars, small-molecule generics, injectables, GLP-1s and more.

More from Policy & Regulation

Overseas API Manufacturing Identified As Key Vulnerability In US Supply Chain

After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.

Sawai Outlook Improves But Japanese Generics Continue To Suffer Under NHI Price Cuts

 
• By 

Japanese generics giant Sawai appears to be turning a corner, but the impact of National Health Insurance pricing revisions continues to hold the firm – and the rest of the country’s generics industry – back.

Biden Launches Effort To Strengthen US Pharmaceutical Supply Chain

 
• By 

A fresh executive order from US president Joe Biden calls for short-term and long-term study, broad consultation, and co-ordination with allies on the domestic supply chain.